PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2016European Heart Journal694 citationsOpen Access

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

View Full Paper
GGGeeta GulatiSHSiri Lagethon HeckARAnne Hansen Ree

Structured PICO

Does concomitant treatment with candesartan and metoprolol prevent early decline in global left ventricular function in patients treated for early breast cancer with adjuvant anthracycline-containing regimens?

P
Population
Patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation
I
Intervention
Candesartan and metoprolol
C
Comparator
Placebo
O
Outcome
Early decline in global left ventricular functionsurrogate

Concomitant treatment with candesartan protects against early decline in left ventricular function in patients receiving anthracycline-containing regimens for early breast cancer.

Abstract

In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gulati et al. (2016) studied this question.

synapsesocial.com/papers/69d56e1c75589c71d767d3c7https://doi.org/10.1093/eurheartj/ehw022
Ask AI
Helpful
Bookmark
Share
View Full Paper